scholarly journals TIME TO SECOND LINE BRUTON TYROSINE KINASE THERAPY AND AGE AT ITS INITIATION ARE STRONGLY ASSOCIATED WITH SUBSEQUENT OVERALL SURVIVAL IN PATIENTS WITH FIRST RELAPSE OF MANTLE CELL LYMPHOMA

2021 ◽  
Vol 39 (S2) ◽  
Author(s):  
D. Villa ◽  
A. Jiang ◽  
N. Crosbie ◽  
S. Rule ◽  
R. McCulloch ◽  
...  
Keyword(s):  
Overall Survival ◽  
Tyrosine Kinase ◽  
Mantle Cell Lymphoma ◽  
Cell Lymphoma ◽  
Second Line ◽  
Mantle Cell ◽  
Bruton Tyrosine Kinase ◽  
First Relapse

Bruton tyrosine kinase is commonly overexpressed in mantle cell lymphoma and its attenuation by Ibrutinib induces apoptosis

2013 ◽  
Vol 37 (10) ◽  
pp. 1271-1277 ◽  
Author(s):  
Munevver Cinar ◽  
FaridSaei Hamedani ◽  
Zhicheng Mo ◽  
Bekir Cinar ◽  
Hesham M. Amin ◽  
...  
Keyword(s):  
Tyrosine Kinase ◽  
Mantle Cell Lymphoma ◽  
Cell Lymphoma ◽  
Mantle Cell ◽  
Bruton Tyrosine Kinase

scholarly journals A Phase III study of zanubrutinib plus rituximab versus bendamustine plus rituximab in transplant-ineligible, untreated mantle cell lymphoma

2020 ◽  
Author(s):  
Martin Dreyling ◽  
Constantine S Tam ◽  
Michael Wang ◽  
Stephen D Smith ◽  
Marco Ladetto ◽  
...  
Keyword(s):  
Tyrosine Kinase ◽  
Mantle Cell Lymphoma ◽  
Kinase Inhibitor ◽  
Cell Lymphoma ◽  
Phase Iii ◽  
Cell Transplant ◽  
Clinical Trial Registration ◽  
Mantle Cell ◽  
Bruton Tyrosine Kinase ◽  
Phase Iii Study

Mantle cell lymphoma is an aggressive B-cell malignancy. Current frontline chemoimmunotherapies produce high response rates but relapse is inevitable. Furthermore, the elderly and those with comorbidities are precluded from standard regimens and stem cell transplant, leaving them with limited options. Targeted therapies, including Bruton tyrosine kinase inhibitors, are an effective treatment strategy in mantle cell lymphoma. Zanubrutinib is a potent next-generation Bruton tyrosine kinase inhibitor that has demonstrated complete and sustained Bruton tyrosine kinase occupancy, minimal off-target effects and favorable pharmacokinetic/pharmacodynamic properties. Described herein is an ongoing Phase III study comparing the efficacy and safety of zanubrutinib plus rituximab followed by zanubrutinib monotherapy versus bendamustine plus rituximab followed by observation in transplant-ineligible patients with previously untreated mantle cell lymphoma. Clinical Trial Registration: NCT04002297 ( ClinicalTrials.gov )

Sign in / Sign up

Export Citation Format

Share Document